about
Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?Psoriasis and Atopic Dermatitis.Psoriasis and multiple sclerosis: is there a link?Long-term treatment of chronic plaque psoriasis with biological drugs can control platelet activation: targeting the bridge between inflammation and atherothrombosis.Metabolic syndrome in patients with psoriasis: A comparative study.Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database.The brain-skin connection: role of psychosocial factors and neuropeptides in psoriasis.Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment.A practical approach to monitoring patients on biological agents for the treatment of psoriasisEtanercept in the treatment of plaque psoriasisPsoriasis and the risk of pneumonia: a population-based study.'On the surface': a qualitative study of GPs' and patients' perspectives on psoriasis.Systemic role for vitamin d in the treatment of psoriasis and metabolic syndromeA cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy.Psoriasis and increased prevalence of hypertension and diabetes mellitus.Comorbidities of Psoriasis - Exploring the Links by Network Approach.Evaluating practice patterns for managing moderate to severe plaque psoriasis: role of the family physician.Evaluation of the Potential Association between NOS Gene Polymorphisms (iNOS G-954C and eNOS G894T) and PsoriasisProviding Guidance for Patients With Moderate-to-Severe Psoriasis Who Are Candidates for Biologic Therapy: Role of the Nurse Practitioner and Physician Assistant.Prevalence of Metabolic Syndrome in Psoriasis Patients and its Relation to Disease Duration: A Hospital Based Case-Control StudyMetabolic syndrome and skin: psoriasis and beyond.Update on the natural history and systemic treatment of psoriasis.Psychoneuroimmunology: the example of psoriasisIllness acceptance degree versus intensity of psychopathological symptoms in patients with psoriasis.An observational study on the obesity and metabolic status of psoriasis patients.Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions.Burden of skin diseases.Depression and quality of life in psoriasis.Psoriasis comorbidities.Evaluation of subclinical atherosclerosis in Egyptian psoriatic patients.Psoriasis and non-alcoholic fatty liver disease.Reviewing concepts in the immunopathogenesis of psoriasis.Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence.Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper.Factors affecting response to biologic treatment in psoriasis.PSOCUBE, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidence-based algorithm.Association between methylenetetrahydrofolate reductase C677T polymorphism and psoriasis: A meta-analysis.Motivational interviewing-based training enhances clinicians' skills and knowledge in psoriasis: findings from the Pso Well® study.Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis.
P2860
Q26767276-4F0DFBB0-177B-42B6-B46C-4719684F3083Q30238648-7383CCD9-07FD-4001-BB9D-448A7461903BQ33636180-659B8B9A-2437-4848-AB02-483808F243BAQ33645863-84AF7DC6-57C7-41F4-8B3D-135E74B0163CQ33647531-F1747919-6DA6-4C73-BB1A-FC188AEDEFD0Q33651728-98DAE3BC-F9EE-4827-A405-25D1C53C0C62Q34080687-4E38E301-46A2-457F-AFB5-AB567952D0D9Q34103030-FE4239F6-30E6-4E6F-8D37-1F9D7681B4BAQ34156420-9D9A1B10-BFDE-4ABE-A382-DC185900DCE8Q34620263-BCC0095F-D1BA-40FD-972F-E15763D8C88CQ34777002-5812D2FD-2D33-43B1-A428-7B44AFAD996BQ35020447-8502045B-3BA2-484F-9F53-987C9A72EA38Q35089915-373B6E33-2D37-4440-ABCF-D92046254FC2Q35205458-6B9CC03E-3A99-49DC-9118-9950F12EF19DQ35564637-29C571BD-49FA-4451-B552-2A04980E1AF9Q35953653-1728D63E-19B6-41A1-9FDF-2C36AC9870ABQ36091617-E551EC31-E522-4160-A4B7-49CAB74AE2E1Q36534531-B7DD964A-56B6-41D9-AFA6-B53C3D8102BBQ36628064-F27BFAEC-069A-42AE-AB68-31E377BF2276Q36708804-1691AD56-D911-4B94-927F-18E23DB04463Q37054329-F14080C5-A495-402C-8973-12B768379C04Q37081486-35689656-774D-48D8-9BE9-284F01866412Q37240971-055E79AD-A93C-4B8B-B3C8-395FEF0A7C23Q37327238-4EF6755A-2780-48D0-A42A-BE534B5D48B1Q37408380-4075BC8A-E714-4C2A-8F26-9B0EAD7233AAQ37418809-E67B5A02-61FD-4196-89F3-70FD2966F892Q37519631-130FEC55-E920-4DED-853A-E5DC978A0521Q37566094-B84B6EA0-C4D7-4953-A013-A631B8E7021AQ37607422-8D5D100F-2B6D-4AAF-8B68-555CD0E7C97BQ37690591-033877A9-FE8D-4A78-A1AD-A4DF39C487C2Q37788777-0AE67D60-BF63-4448-92E1-9787E30C0169Q37979135-44589887-F404-4E1B-B6EC-384CD7F079DBQ38027577-444E7053-BD52-49F2-9834-9B5E591BC083Q38189108-67A15C86-5D3E-4788-916D-19F0556CB355Q38232919-10E9BAE7-E18F-46DC-8113-D972BF773762Q38265056-EE9AA545-9AB4-4601-AF46-254BBF6D850EQ38388193-2C59744E-C12E-48A6-8AF4-EABDFF4A1994Q38845839-45F3B3B1-7236-45BE-A16E-8514000AE69CQ39837952-14CECE31-FB98-497F-A9B9-0A483A2A33ACQ39926646-A87F3644-6268-4FFD-A947-D63E3C451B39
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Psoriasis comorbidities.
@en
type
label
Psoriasis comorbidities.
@en
prefLabel
Psoriasis comorbidities.
@en
P2093
P2860
P1476
Psoriasis comorbidities.
@en
P2093
Alice B Gottlieb
Frank Dann
P2860
P356
10.1080/09546630701364768
P577
2008-01-01T00:00:00Z